The effects of the restatement on the Company’s consolidated balance sheet as of March 31, 2016 are as follows (in thousands):


	March 31, 2016
	As Previously Reported			Restatement Adjustments			As Restated
Consolidated Balance Sheet:
Prepaid expenses and other current assets	$	2,826		$	(746	)	$	2,080
Total current assets		27,504			(746	)		26,758
Total assets		51,589			(746	)		50,843
Accrued expenses		3,168			(291	)		2,877
Deferred revenue		1,253			4,455			5,708
Total current liabilities		8,513			4,164			12,677
Total liabilities		11,813			4,164			15,977
Accumulated deficit		(240,044	)		(4,910	)		(244,954	)
Total stockholders’ equity		39,226			(4,910	)		34,316
Total liabilities and stockholders’ equity		51,589			(746	)		50,843

The effects of the restatement on the Company’s consolidated balance sheet as of December 31, 2015 are as follows (in thousands):


	December 31, 2015
	As Previously Reported			Restatement Adjustments			As Restated
Consolidated Balance Sheet:
Prepaid expenses and other current assets	$	1,674		$	(802	)	$	872
Total current assets		26,736			(802	)		25,934
Total assets		51,379			(802	)		50,577
Accrued expenses		4,158			(728	)		3,430
Deferred revenue		1,336			2,831			4,167
Total current liabilities		7,736			2,103			9,839
Total liabilities		11,412			2,103			13,515
Accumulated deficit		(240,406	)		(2,905	)		(243,311	)
Total stockholders’equity		39,417			(2,905	)		36,512
Total liabilities and stockholders’ equity		51,379			(802	)		50,577

The tables below show the effects of the restatement on the Company’s consolidated statements of operations, consolidated statements of comprehensive income (loss) and consolidated statements of cash flows for the quarters ended March 31, 2016 and 2015 (in thousands, except for per share data). In each case, the tax effect of the adjustments was considered insignificant.


	Three Months Ended March 31, 2016
	As Previously Reported			Restatement Adjustments			As Restated
Consolidated Statement of Operations:
Product revenues	$	7,949		$	(1,624	)	$	6,325
Total revenues		12,101			(1,624	)		10,477
Gross profit		5,751			(1,624	)		4,127
Research and development		1,752			381			2,133
Total operating expenses		5,484			381			5,865
Income (loss) from operations		267			(2,005	)		(1,738	)
Income (loss) before taxes		366			(2,005	)		(1,639	)
Net income (loss)		362			(2,005	)		(1,643	)
Basis net income (loss) per share	$	0.03		$	(0.18	)	$	(0.15	)
Diluted net income (loss) per share	$	0.03		$	(0.18	)	$	(0.15	)
Consolidated Statement of Comprehensive Income (Loss):
Net income (loss)	$	362		$	(2,005	)	$	(1,643	)
Comprehensive loss		(302	)		(2,005	)		(2,307	)
Consolidated Statement of Cash Flows:
Net income (loss)	$	362		$	(2,005	)	$	(1,643	)
Prepaid expenses and other current assets		(1,152	)		746			(406	)
Accrued expenses		(922	)		(365	)		(1,287	)
Deferred revenue		(275	)		1,624			1,349


	Three Months Ended March 31, 2015
	As Previously Reported			Restatement Adjustments			As Restated
Consolidated Statement of Operations:
Product revenues	$	4,875		$	710		$	5,585
Total revenues		8,326			710			9,036
Gross profit		3,448			710			4,158
Loss from operations		(831	)		710			(121	)
(Loss) income before taxes		(687	)		710			23
Net (loss) income		(692	)		710			18
Basis net (loss) income per share	$	(0.06	)	$	0.06		$	0.00
Diluted net (loss) income per share	$	(0.06	)	$	0.06		$	0.00
Consolidated Statement of Comprehensive Loss:
Net (loss) income	$	(692	)	$	710		$	18
Comprehensive loss		(1,679	)		710			(969	)
Consolidated Statement of Cash Flows:
Net (loss) income	$	(692	)	$	710		$	18
Deferred revenue		(191	)		(710	)		(901	)